|
|
|
|
|
| CHADS2 scores predict adverse clinical events in patients with triple vessel coronary disease |
| LI?AO Chen-jun, WANG Qiu-shi, MIAO Fei, WU Hong-chao, LI Gong-hui, WU Xiao-yan, LIN Yong-luan,LIU Peng, LIU Ying-feng |
| Department of Cardiovascular Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, China |
|
|
|
|
Abstract Objective CHADS2 score is not only useful in predicting stroke in patients with atrial fibrillation, but also in predicting adverse clinical events with those with acute coronary syndrome. This
present study aimed to explore the association between CHADS2 score and adverse clinical events in patients with triple-vessel diseases/left main disease (TVD/LMD). Methods A total of 995 patients with TVD were retrospectively involved. They were divided into three groups according to CHADS2 score: 0 to 1, 2 to 3, and 4 to 6. Results The association of CHADS2 score with 1 year major adverse clinical events (MACEs) including all-cause death, re-hospitalization for heart failure, myocardial infarction, revascularization and stroke were investigated. A strong positive association between tertiles of CHADS2 (0 to 1, 2 to 3, and 4 to 6) score and its each component including chronic heart failure, hypertension, older age, diabetes, and previous stroke could be observed. Also, increased tertiles of CHADS2 score was strongly associated with higher Syntax score (SS), impaired left ventricular ejection fraction, and reduced renal function. After adjusted the confounding factors, the tertiles of CHADS2 score (2 to 3 and 4 to 6, respectively) remained independent predictors of adverse events in separate multivariate Logistic Regres⁃sion analysis. Results from receiver operating characteristic (roc) curves revealed chads2 score had similar performance with syntax score and age creatinine ejection fraction score but inferior to clinical syntax score in predicting 1 year MACEs in TVD/LMD patients. Conclusion CHADS2 score might be a potential tool to provide prognostic information and help physicians to identify their patients at high risk.
|
|
Received: 12 January 2016
|
|
Corresponding Authors:
LIU Ying-feng, E-mail: wisdom1219@sina.com
|
|
|
|
| [1] Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three- vessel disease and left main coronary disease: 5- year follow- up of the randomised, clinical SYNTAX trial[J]. Lancet,2013,381(9867):629-638.
[2] Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J]. J Am Coll Cardiol,2011, 58(24):e44-122.
[3] Campos CM, Stanetic BM, Farooq V, et al. Risk stratification in 3-vessel coronary artery disease: Applying the SYNTAX Score Ⅱ in the Heart Team Discussion of the SYNTAX Ⅱ Trial[J]. Catheter Cardiovasc Interv, 2015, 86(6):E229-238.
[4] European Heart Rhythm Association, European Association for Cardio- Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC) [J]. Eur Heart J, 2010, 31(19):2369-2429.
[5] Cha MJ, Lee HS, Kim YD, et al. The association between asymptomatic coronary artery disease and CHADS2 and CHA2DS2-VAScscores in patients with stroke[J]. Eur J Neurol, 2013,20(9):1256-1263.
[6] Huang SS, Chen YH, Chan WL, et al. Usefulness of the CHADS2 score for prognostic stratification of patients with acute myocardial infarction[J]. Am J Cardiol, 2014, 114(9):1309-1314.
[7] Hoshino T, Ishizuka K, Shimizu S, et al. CHADS2 score predicts functional outcome of stroke in patients with a history of coronary artery disease[J]. J Neurol Sci, 2013, 331(1-2):57-60.
[8] Lehmann R, Fichtlscherer S, Schächinger V, et al. Complete revascularization in patients undergoing multivessel PCI is an independent predictor of improved long-term survival[J]. J Interv Cardiol,2010, 23(3):256-263.
[9] Rosborough TK, Shepherd MF, Couch PL. Selecting an equation to estimate glomerular filtration rate for use in renal dosage adjustment of drugs in electronic patient record systems[J]. Pharmacotherapy,2005, 25(6):823-830.
[10] Kovacic JC, Limaye AM, Sartori S, et al. Comparison of six risk scores in patients with triple vessel coronary artery disease undergoing PCI:competing factors influence mortality, myocardial infarction and target lesion revascularization[J]. Catheter Cardiovasc Interv,2013, 82(6):855-868.
[11] Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves[J]. BMC Bioinfor⁃matics,2011, 12:77.
[12] Wykrzykowska JJ, Garg S, Girasis C, et al. Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial[J]. J Am Coll Cardiol, 2010,56(4):272-277.
[13] Farooq V, Head SJ, Kappetein AP, ey al. Widening clinical applications of the SYNTAX Score[J]. Heart,2014,100(4):276-287.
[14] Girasis C, Garg S, Räber L, et al. SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of SIRolimus-eluting stent compared with Paclitaxel-eluting stent for coronary revascularization (SIRTAX) trial[J]. Eur Heart J,2011,32(24):3115-3127. |
|
|
|
Address: 1 North 2nd Street,
Zhongguancun, 
